The role of glatiramer acetate in the early treatment of multiple sclerosis
David W BrandesHope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USAAbstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatm...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2010
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/61356ac105164c298ae585332c41ab39 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|